SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a ...
Targeted genetic medicines are reshaping the future of cancer treatment by improving the precision of therapeutic delivery while addressing the challenges ...
Dasher Neuroscience Holdings Inc. (TPEx: 7829) ("Dasher Neuroscience"), an AI-driven biopharmaceutical company focused on central nervous system (CNS) dr...
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and pote...
-Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasir...
Sanofi announced the discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis ...
The issuer is solely responsible for the content of this announcement. Fresenius is further expanding its access to innovation networks through its own co...
Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, announced that dosing has begun in a Phase 1 clinical study evaluating B...
A consortium of European and US-based investors and Nobias Therapeutics announced the launch of Synaptiq Therapeutics, a privately held, clinical-stage bio...
Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK...
This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib a...
Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to...
BW-41012 represents the eighth clinical candidate from Argo's innovative RNAi pipeline, and is being evaluated for the prevention of thromboembolic disea...
Aims to Raise Capital to Fund Global Clinical Studies for LNP7457 (PRMT5) & LNP8701 (SOS1) Global pharmaceutical leader Lupin Limited &n...
© 2026 Biopharma Boardroom. All Rights Reserved.
